Liposomes as carriers for allergy immunotherapy
Liposomes as carriers for allergy immunotherapy
复制标题
脂质体作为过敏免疫治疗的载体
DOI：
--
复制
发表时间：
1991
影响因子：
6.1
通讯作者：
J. Carreira
中科院分区：
文献类型：
--
作者：
C. Audera;J. Ramírez;E. Soler;J. Carreira
为了获得用于过敏免疫治疗的有效但更安全的疫苗，已经考虑了使用脂质体作为佐剂的可能性，因为它们已被证明具有低毒性、佐剂性质和在体内将包封的物质在其内部维持一段时间的能力。将过敏原提取物包封到中性、带正电荷和带负电荷的DPPC：胆固醇脂质体中的不同方法已经被研究，并且研究了由这些在小鼠中引起的免疫应答，并与对游离过敏原或其他佐剂（如氢氧化铝）的免疫应答进行比较。获得的结果表明，包封在所有三种类型的脂质体中的过敏原引起的特异性IgG水平的增加高于游离过敏原引起的特异性IgG水平的增加，然而，当使用带正电荷的（DPPC. -胆固醇硬脂胺）脂质体时，包封效率和特异性IgG升都更高。特异性IgF阳性和中性脂质体中的变应原水平低于阴性脂质体中的变应原水平或吸附到Al（OH）3上的变应原水平。在通过不同方法制备的脂质体的行为中没有发现差异（结果从来自不同组小鼠的合并血清获得，因此没有统计数据）。这些结果证实了脂质体用于变态反应免疫治疗的免疫佐剂作用。有必要进一步研究以确定其缺乏毒性，药代动力学研究和人体临床研究，以确认其对人类使用的充分性和优于当前免疫治疗方法的优势。
With the aim of obtaining an efficient but safer vaccine for allergy immunotherapy, the possibility of using liposomes as adjuvants has been considered given their proven low toxicity, adjuvant properties and ability to maintain the encapsulated substance in their interior for sonic time in vivo. Different methods of encapsulating allergenic extracts into neutral, positively, and negatively charged DPPC: cholesterol liposomes have been investigated and the immune response provoked by these in mice was studied and compared to the immune response to free allergen or other adjuvants such as aluminium hydroxide. The results obtained show that allergen encapsulated in all three types of liposomes elicit an increase in specific IgG levels higher than that provoked by free allergen, however, both encapsulation efficiency and specific FgG litre were higher when positively charged (DPPC.‐cholesterol steurylamine) liposomes were used. Specific IgF. levels to allergen in positive and neutral liposomes was lower than to allergen in negative liposomes or adsorbed to A1(OH)3 No differences were found in the behaviour of liposomes prepared by different methods (the results were obtained from pooled sera from different groups of mice so there is no statistical data). These results confirm the immunoadjuvanl effect of liposomes for allergy immunotherapy. Further studies to determine their lack of toxicity, pharmacokinetic studies and human clinical studies are necessary to confirm their adequacy for human use and advantage over current immunotherapy methods.